Omnipresent - Video

Filter By Therapeutic Area

Reproductive Health

Allergy & Immunology

Gastroenterology

Interventional Cardiology

Microbiology & Infectious Diseases

Filter By Content Type

Treatment and outcome of CML patients from the EUTOS population-based registry

Venetoclax (ABT-199/GDC-0199) plus rituximab shows promise in relapsed/refractory CLL

Adding elotuzumab to standard treatment for myeloma reduced disease progression

Phase 3 CheckMate 067 trial of nivolumab in previously untreated advanced melanoma

Whole Brain Radiation Therapy is More Harmful Than Beneficial for Small Brain Metastases

Elective Neck Dissection Improved Survival in Early Node-Negative Oral Cancer

Improved Cancer Treatments Linked to Reduced Late Mortality in Childhood Cancer Survivors

Combined Nivolumab and Ipilimumab or Monotherapy Shown Promise in Untreated Melanoma

Novel JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis

Obinutuzumab Doubles Remission Duration in Relapsed, Indolent Non-Hodgkin Lymphoma

Daratumumab Shows Promise in Heavily Treatment-Resistant Multiple Myeloma

New Ibrutinib Combination Regimen Shows Substantial Benefits in Relapsed CLL

Dr A. Erdem Canda Chairs a Discussion on the Trends and Developments in the Field of Endourology

An Interview with Dr. Abolfazl Hosseni at the 11th National Endourology Congress, Discussing the Developing Treatment in Bladder Cancer

An Interview with Dr. Abhay Rane at the 11th National Endourology Congress, Discussing the Key Points of the Upcoming World Congess of Endourology

An Interview with Dr. John W. Davis at the 11th National Endourology Congress, Discussing the Key Points from the Congress

An Interview with Dr. Kevin C. Zorn at the 11th National Endourology Congress, Discussing Developments within the Field

Nivolumab Shows Highly Promising Activity in Advanced Liver Cancer in Early-Stage Trial

Genomic Marker Predicts Anti-PD-1 Response in Several Cancers

Nivolumab Extends Survival for Patients With the Most Common Lung Cancer

An introduction to ASCO 2015 by the 2014-15 president, Peter Paul Yu, MD, FACP, FASCO

PARP inhibitors and the EMBRACA study of talazoparib in BRCA-related metastatic breast cancer

The mechanisms of BRCA-related breast cancer and molecular profiling

Current research into treatments for BRCA-related breast cancer and the phase 3 EMBRACA trial

The role of BRCA and PARP in DNA repair and BRCA-related breast cancer

The phase 3 EMBRACA study of talazoparib in BRCA-related metastatic breast cancer

BRCA-related breast cancer: the implications of genetic testing and potential management options

Dr Keith Stewart chairs a discussion on early treatment and novel therapies for multiple myeloma